Skip to main content
Premium Trial:

Request an Annual Quote

Icoria, in Transition, Posts 21-Percent Slide in Q2 Revenue; Restructuring Ongoing

NEW YORK, Aug. 16 (GenomeWeb News) - Icoria yesterday reported reduced revenues and narrowed losses for the second quarter of 2005.


Revenues declined 21 percent to $5 million from $6.3 million during the year-ago quarter. While healthcare revenues grew 11 percent, to $2.5 million, agriculture revenues declined by 39 percent, to $2.4 million, mainly due to the sale of Icoria's agricultural genomics business to Monsanto earlier this year.


R&D expenses declined to $5.5 million from $6.8 million during the second quarter of last year.


Icoria's net loss fell 16 percent, to $3 million, or $.08 per share, down from $3.6 million, or $.10 per share, for the same period last year.


"The second quarter was a period of transition for Icoria, and our financial results reflect this," said Douglas Morton, Icoria's interim CEO, in a statement. "We are working to restructure our cost base and to minimize our burn rate without impairing the operations and research activities on which Icoria is building its future."


As of June 30, Icoria had $8.7 million in cash, cash equivalents, and short-term investments.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.